Product/Composition:- | Clarithromycin tablets |
---|---|
Strength:- | 250 mg, 500 mg |
Form:- | Tablet |
Reference Brands:- | Biaxin (EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking translocation. It effectively treats respiratory, skin, and Helicobacter pylori infections. Benefits include rapid, broad-spectrum antibacterial activity, good tissue penetration, and convenient oral dosing, making it a reliable choice for managing various bacterial infections.
Clarithromycin tablets are approved in the EU and US for respiratory, skin, and Helicobacter pylori infections. In the EU, brands like Biaxin are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on comprehensive clinical data, with generic options available. Both regions require detailed dossiers and pharmacovigilance plans for approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for clarithromycin tablets, ensuring adherence to European and US standards for safe, effective antibiotic therapy while navigating complex regulatory processes seamlessly.